Biotech · Private company

Array Biopharma, now a wholly owned subsidiary of Pfizer

Track this companyFree. Adds Array Biopharma, now a wholly owned subsidiary of Pfizer to your Dealase workspace and tells you when its record changes.

Clinical trials230 recruiting or active

Pipeline programs29From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availablePrivate: no SEC financials

Pipeline29

AEB071Phase 2 · Uveal MelanomaClinicalTrials.gov · fetched Nov 12, 2026
ARRY-438162, MEK inhibitor; oralPhase 2 · Rheumatoid ArthritisClinicalTrials.gov · fetched Nov 12, 2026
LGX818Phase 2 · Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
MEK162Phase 2 · CardiomegalyClinicalTrials.gov · fetched Nov 12, 2026
MEK162Phase 2 · Uveal MelanomaClinicalTrials.gov · fetched Nov 12, 2026
ARRY-142886, MEK inhibitor; oralPhase 1 · Advanced CancerClinicalTrials.gov · fetched Nov 12, 2026
ARRY-300, MEK inhibitor; oralPhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
ARRY-334543, EGFR/ErbB2 inhibitor; oralPhase 1 · Advanced CancerClinicalTrials.gov · fetched Nov 12, 2026
ARRY-371797, p38 inhibitor; oralPhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
ARRY-371797, p38 inhibitor; oralPhase 1 · Rheumatoid ArthritisClinicalTrials.gov · fetched Nov 12, 2026
ARRY-382, cFMS inhibitor; oralPhase 1 · Metastatic CancerClinicalTrials.gov · fetched Nov 12, 2026
ARRY-403, glucokinase activator; oralPhase 1 · Type 2 DiabetesClinicalTrials.gov · fetched Nov 12, 2026
ARRY-438162 (MEK162), MEK inhibitor; oralPhase 1 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
ARRY-502Phase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
ARRY-520, KSP(Eg5) inhibitor; intravenousPhase 1 · Multiple Myeloma, Plasma Cell LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
ARRY-520, KSP(Eg5) inhibitor; intravenousPhase 1 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
ARRY-614, p38/Tie2 inhibitor; oralPhase 1 · Myelodysplastic SyndromesClinicalTrials.gov · fetched Nov 12, 2026
BKM120 + MEK162Phase 1 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
Bortezomib, proteasome inhibitor; intravenous or subcutaneousPhase 1 · Multiple Myeloma, Plasma Cell LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
Capecitabine, 5-fluorouracil prodrug; oralPhase 1 · Advanced CancerClinicalTrials.gov · fetched Nov 12, 2026
Dexamethasone, steroid; oralPhase 1 · Multiple Myeloma, Plasma Cell LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
Docetaxel, mitotic inhibitor; intravenousPhase 1 · Advanced CancerClinicalTrials.gov · fetched Nov 12, 2026
Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneousPhase 1 · Multiple Myeloma, Plasma Cell LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneousPhase 1 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
MEK162Phase 1 · Hepatic ImpairmentClinicalTrials.gov · fetched Nov 12, 2026
MEK162 + RAF265Phase 1 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
MEK162, MEK inhibitor; oralPhase 1 · Epithelial Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
Paclitaxel, mitotic inhibitor; intravenousPhase 1 · Epithelial Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
Prophylactic growth factors; subcutaneousPhase 1 · Advanced CancerClinicalTrials.gov · fetched Nov 12, 2026

Clinical trials23

Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLCPHASE2 · WITHDRAWN · started Jun 1, 2015ClinicalTrials.gov NCT02109653 · fetched Nov 12, 2026
MEK162 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic FunctionPHASE1 · TERMINATED · started Mar 1, 2014ClinicalTrials.gov NCT02050815 · fetched Nov 12, 2026
A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal MelanomaPHASE1_PHASE2 · TERMINATED · started Aug 1, 2013ClinicalTrials.gov NCT01801358 · fetched Nov 12, 2026
A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal CancerPHASE1 · COMPLETED · started Jul 1, 2012ClinicalTrials.gov NCT01649336 · fetched Nov 12, 2026
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEK162 in Noonan Syndrome Hypertrophic CardiomyopathyPHASE2 · WITHDRAWN · started Feb 1, 2012ClinicalTrials.gov NCT01556568 · fetched Nov 12, 2026
A Study of ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic SyndromesPHASE1 · COMPLETED · started Jan 1, 2012ClinicalTrials.gov NCT01496495 · fetched Nov 12, 2026
Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor PatientsPHASE1 · COMPLETED · started Aug 1, 2011ClinicalTrials.gov NCT01363232 · fetched Nov 12, 2026
MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E MutationsPHASE1 · COMPLETED · started Jun 1, 2011ClinicalTrials.gov NCT01352273 · fetched Nov 12, 2026
A Safety Study of ARRY-502 in Healthy SubjectsPHASE1 · COMPLETED · started May 1, 2011ClinicalTrials.gov NCT01349725 · fetched Nov 12, 2026
A Study of ARRY-382 in Patients With Selected Advanced or Metastatic CancersPHASE1 · COMPLETED · started Mar 1, 2011ClinicalTrials.gov NCT01316822 · fetched Nov 12, 2026
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple MyelomaPHASE1 · COMPLETED · started Dec 1, 2010ClinicalTrials.gov NCT01248923 · fetched Nov 12, 2026
A Study of ARRY-438162 (MEK162) in Patients With Advanced CancerPHASE1 · COMPLETED · started Aug 1, 2009ClinicalTrials.gov NCT00959127 · fetched Nov 12, 2026
A Safety Study of ARRY-403 in Patients With Type 2 DiabetesPHASE1 · COMPLETED · started Aug 1, 2009ClinicalTrials.gov NCT00952198 · fetched Nov 12, 2026
A Study of ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic SyndromePHASE1 · COMPLETED · started Jun 1, 2009ClinicalTrials.gov NCT00916227 · fetched Nov 12, 2026
A Safety Study of ARRY-300 in Healthy SubjectsPHASE1 · COMPLETED · started Jan 1, 2009ClinicalTrials.gov NCT00828165 · fetched Nov 12, 2026
A Study of ARRY-334543 and Docetaxel in Patients With Advanced CancerPHASE1 · COMPLETED · started Jan 1, 2009ClinicalTrials.gov NCT00833326 · fetched Nov 12, 2026
A Safety Study of ARRY-371797 in Healthy SubjectsPHASE1 · COMPLETED · started Oct 31, 2008ClinicalTrials.gov NCT00790049 · fetched Nov 12, 2026
A Study of ARRY-371797 in Patients With Rheumatoid ArthritisPHASE1 · COMPLETED · started Jul 1, 2008ClinicalTrials.gov NCT00729209 · fetched Nov 12, 2026
A Study of ARRY-334543 and Capecitabine in Patients With Advanced CancerPHASE1 · COMPLETED · started Jun 1, 2008ClinicalTrials.gov NCT00710736 · fetched Nov 12, 2026
A Study of ARRY-438162 in Patients With Rheumatoid ArthritisPHASE2 · COMPLETED · started Mar 1, 2008ClinicalTrials.gov NCT00650767 · fetched Nov 12, 2026
A Study of ARRY-520 in Patients With Advanced CancerPHASE1 · COMPLETED · started Apr 1, 2007ClinicalTrials.gov NCT00462358 · fetched Nov 12, 2026
A Study of ARRY-334543 in Patients With Advanced CancerPHASE1 · COMPLETED · started Jan 1, 2006ClinicalTrials.gov NCT00278902 · fetched Nov 12, 2026
A Study of ARRY-142886 in Patients With Advanced CancerPHASE1 · COMPLETED · started Jun 1, 2004ClinicalTrials.gov NCT00085787 · fetched Nov 12, 2026